Takeda Pharmaceutical (NYSE:TAK) Reaches New 52-Week High – Time to Buy?
by Renee Jackson · The Cerbat GemShares of Takeda Pharmaceutical Co. (NYSE:TAK – Get Free Report) reached a new 52-week high on Tuesday . The company traded as high as $15.94 and last traded at $15.9050, with a volume of 469706 shares changing hands. The stock had previously closed at $15.69.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold”.
Get Our Latest Analysis on Takeda Pharmaceutical
Takeda Pharmaceutical Stock Performance
The company has a current ratio of 1.37, a quick ratio of 0.76 and a debt-to-equity ratio of 0.61. The company’s fifty day simple moving average is $14.54 and its 200 day simple moving average is $14.65. The stock has a market capitalization of $52.01 billion, a P/E ratio of 203.69 and a beta of 0.03.
Takeda Pharmaceutical (NYSE:TAK – Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The company reported $0.44 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.44. Takeda Pharmaceutical had a return on equity of 10.32% and a net margin of 0.86%.The company had revenue of $7.30 billion for the quarter, compared to the consensus estimate of $8.01 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. As a group, sell-side analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the stock. Park Avenue Securities LLC increased its holdings in Takeda Pharmaceutical by 14.1% in the 4th quarter. Park Avenue Securities LLC now owns 37,684 shares of the company’s stock worth $587,000 after acquiring an additional 4,662 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Takeda Pharmaceutical by 37.7% in the third quarter. JPMorgan Chase & Co. now owns 247,529 shares of the company’s stock worth $3,624,000 after buying an additional 67,770 shares in the last quarter. Allworth Financial LP boosted its stake in Takeda Pharmaceutical by 8.3% during the third quarter. Allworth Financial LP now owns 12,305 shares of the company’s stock valued at $180,000 after buying an additional 948 shares during the last quarter. First Affirmative Financial Network grew its holdings in Takeda Pharmaceutical by 16.8% during the 3rd quarter. First Affirmative Financial Network now owns 41,852 shares of the company’s stock valued at $613,000 after buying an additional 6,025 shares in the last quarter. Finally, Coldstream Capital Management Inc. increased its stake in Takeda Pharmaceutical by 136.8% in the 3rd quarter. Coldstream Capital Management Inc. now owns 23,828 shares of the company’s stock worth $349,000 after acquiring an additional 13,765 shares during the last quarter. Institutional investors own 9.17% of the company’s stock.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.
Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.